BCRP/ABCG2 Inhibition Sensitizes Hepatocellular Carcinoma Cells to Sorafenib

The multikinase inhibitor, sorafenib (Nexavar®, BAY43-9006), which inhibits both the Raf/MEK/ERK pathway and several receptor tyrosine kinases (RTKs), has shown significantly therapeutic benefits in advanced hepatocellular carcinoma (HCC). However, not all HCC patients respond to sorafenib well and...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Huang, Wei-Chien, Hsieh, Yi-Ling, Hung, Chao-Ming, Chien, Pei-Hsuan, Chien, Yu-Fong, Chen, Lei-Chin, Tu, Chih-Yen, Chen, Chia-Hung, Hsu, Sheng-Chieh, Lin, Yueh-Ming, Chen, Yun-Ju
Format: Artigo
Langue:Inglês
Publié: Public Library of Science 2013
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3877048/
https://ncbi.nlm.nih.gov/pubmed/24391798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0083627
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires